((自动化翻译由路透提供，请见免责声明 ))
11月20日 - ** Viking Therapeutics 股价在收盘前上涨约4%至53.52美元
** 药物开发商在一次医学会议上公布了试验性肝病药物VK2809中期试验的最终结果
** 详细数据显示，接受该药物治疗的患者肝组织纤维化或瘢痕的改善率为44%至57%，而安慰剂的改善率为34%。
** 试验正在对患有严重脂肪肝的患者进行测试，这种病被称为非酒精性脂肪性肝炎(NASH) 或代谢功能障碍相关性脂肪性肝炎(MASH)
** 在该研究中，药物实现了降低肝脏脂肪含量的主要目标，帮助患者解决了 NASH 问题，且纤维化没有恶化 - VKTX
** 数据令人印象深刻，因为它在最高剂量时显示出纤维化获益，在所有剂量时都显示出MASH缓解 - William Blair分析师
** 截至上一交易日收盘，VKTX 的股价已上涨近三倍。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.